Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


Articles published in Neurobiol Dis

Retrieve available abstracts of 100 articles:
HTML format



Single Articles


    November 2022
  1. WISE RM, Wagener A, Fietzek UM, Klopstock T, et al
    Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
    Neurobiol Dis. 2022;175:105920.
    PubMed     Abstract available


  2. SARKAR S
    Microglial ion channels: Key players in non-cell autonomous neurodegeneration.
    Neurobiol Dis. 2022;174:105861.
    PubMed     Abstract available


    October 2022
  3. CHO E, Kim K, Kim H, Cho SR, et al
    Reelin protects against pathological alpha-synuclein accumulation and dopaminergic neurodegeneration after environmental enrichment in Parkinson's disease.
    Neurobiol Dis. 2022 Oct 18:105898. doi: 10.1016/j.nbd.2022.105898.
    PubMed     Abstract available


  4. PUIGROS M, Calderon A, Perez-Soriano A, de Dios C, et al
    Cell-free mitochondrial DNA deletions in idiopathic, but not LRRK2, Parkinson's disease.
    Neurobiol Dis. 2022;174:105885.
    PubMed     Abstract available


  5. RYU DW, Yoo SW, Oh YS, Lee KS, et al
    Comparison of disease progression between brain-predominant Parkinson's disease versus Parkinson's disease with body-involvement phenotypes.
    Neurobiol Dis. 2022;174:105883.
    PubMed     Abstract available


  6. EVANS RC
    Dendritic involvement in inhibition and disinhibition of vulnerable dopaminergic neurons in healthy and pathological conditions.
    Neurobiol Dis. 2022;172:105815.
    PubMed     Abstract available


    September 2022
  7. MARTEL AC, Galvan A
    Connectivity of the corticostriatal and thalamostriatal systems in normal and parkinsonian states: An update.
    Neurobiol Dis. 2022;174:105878.
    PubMed     Abstract available


  8. RUF WP, Palmer A, Dorfer L, Wiesner D, et al
    Thoracic trauma promotes alpha-Synuclein oligomerization in murine Parkinson's disease.
    Neurobiol Dis. 2022 Sep 23:105877. doi: 10.1016/j.nbd.2022.105877.
    PubMed     Abstract available


  9. ZANG NAM, Schneider M, Weiss D
    Cortical mechanisms of movement recovery after freezing in Parkinson's disease.
    Neurobiol Dis. 2022;174:105871.
    PubMed     Abstract available


  10. STOLL AC, Sortwell CE
    Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity.
    Neurobiol Dis. 2022;171:105804.
    PubMed     Abstract available


    August 2022
  11. IMBRIANI P, Martella G, Bonsi P, Pisani A, et al
    Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease.
    Neurobiol Dis. 2022 Aug 22:105851. doi: 10.1016/j.nbd.2022.105851.
    PubMed     Abstract available


  12. OUN A, Sabogal-Guaqueta AM, Galuh S, Alexander A, et al
    The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids.
    Neurobiol Dis. 2022 Aug 10:105837. doi: 10.1016/j.nbd.2022.105837.
    PubMed     Abstract available


  13. WILLIAMS ET, Chen X, Otero PA, Moore DJ, et al
    Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.
    Neurobiol Dis. 2022;170:105768.
    PubMed     Abstract available


  14. ERDMAN HB, Kornilov E, Kahana E, Zarchi O, et al
    Asleep DBS under ketamine sedation: Proof of concept.
    Neurobiol Dis. 2022;170:105747.
    PubMed     Abstract available


    July 2022
  15. BICHSEL O, Stieglitz L, Oertel M, Baumann C, et al
    The modulatory effect of self-paced and cued motor execution on subthalamic beta-bursts in Parkinson's disease: Evidence from deep brain recordings in humans.
    Neurobiol Dis. 2022;172:105818.
    PubMed     Abstract available


  16. TIAN Y, Pan L, Yuan X, Xiong M, et al
    7,8-Dihydroxyflavone ameliorates mitochondrial impairment and motor dysfunction in the alpha-synuclein 1-103 transgenic mice.
    Neurobiol Dis. 2022;169:105736.
    PubMed     Abstract available


  17. RUSSO I, Bubacco L, Greggio E
    LRRK2 as a target for modulating immune system responses.
    Neurobiol Dis. 2022;169:105724.
    PubMed     Abstract available


  18. BURMEISTER AR, Gordevicius J, Paul EN, Houck C, et al
    Maternal Herpesviridae infection during pregnancy alters midbrain dopaminergic signatures in adult offspring.
    Neurobiol Dis. 2022;169:105720.
    PubMed     Abstract available


  19. PAMIES D, Wiersma D, Katt ME, Zhao L, et al
    Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.
    Neurobiol Dis. 2022;169:105719.
    PubMed     Abstract available


    June 2022
  20. TSAFARAS G, Baekelandt V
    The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases.
    Neurobiol Dis. 2022 Jun 30:105806. doi: 10.1016/j.nbd.2022.105806.
    PubMed     Abstract available


  21. O'HANLON ME, Tweedy C, Scialo F, Bass R, et al
    Mitochondrial electron transport chain defects modify Parkinson's disease phenotypes in a Drosophila model.
    Neurobiol Dis. 2022 Jun 25:105803. doi: 10.1016/j.nbd.2022.105803.
    PubMed     Abstract available


  22. MANTIA K, Kostas V, Katerina M
    The promise of the TGF-beta superfamily as a therapeutic target for Parkinson's disease.
    Neurobiol Dis. 2022 Jun 25:105805. doi: 10.1016/j.nbd.2022.105805.
    PubMed     Abstract available


  23. RAUSCHENBERGER L, Behnke J, Grotemeyer A, Knorr S, et al
    Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated alpha-synuclein mouse model of Parkinson's disease.
    Neurobiol Dis. 2022 Jun 21:105798. doi: 10.1016/j.nbd.2022.105798.
    PubMed     Abstract available


  24. KIM J, Lee J, Kim E, Choi JH, et al
    Dopamine depletion can be predicted by the aperiodic component of subthalamic local field potentials.
    Neurobiol Dis. 2022;168:105692.
    PubMed     Abstract available


    May 2022
  25. VOIGT RM, Wang Z, Brown JM, Engen PA, et al
    Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status.
    Neurobiol Dis. 2022 May 30:105780. doi: 10.1016/j.nbd.2022.105780.
    PubMed     Abstract available


  26. SONG B, Feldmann JW, Cao S, Feitosa M, et al
    A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.
    Neurobiol Dis. 2022 May 27:105777. doi: 10.1016/j.nbd.2022.105777.
    PubMed     Abstract available


  27. ABDI IY, Ghanem SS, El-Agnaf OM
    Immune-related biomarkers for Parkinson's disease.
    Neurobiol Dis. 2022;170:105771.
    PubMed     Abstract available


  28. KEENEY MT, Hoffman EK, Farmer K, Bodle CR, et al
    NADPH oxidase 2 activity in Parkinson's disease.
    Neurobiol Dis. 2022 May 13:105754. doi: 10.1016/j.nbd.2022.105754.
    PubMed     Abstract available


  29. BARTL M, Xylaki M, Bahr M, Weber S, et al
    Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease.
    Neurobiol Dis. 2022 May 2:105744. doi: 10.1016/j.nbd.2022.105744.
    PubMed     Abstract available


  30. IZCO M, Carlos E, Alvarez-Erviti L
    Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases.
    Neurobiol Dis. 2022;166:105651.
    PubMed     Abstract available


    April 2022
  31. MAMAIS A, Kaganovich A, Harvey K
    Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson's disease.
    Neurobiol Dis. 2022;169:105721.
    PubMed     Abstract available


    March 2022
  32. CAMPANELLI F, Natale G, Marino G, Ghiglieri V, et al
    Striatal glutamatergic hyperactivity in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 18:105697. doi: 10.1016/j.nbd.2022.105697.
    PubMed     Abstract available


  33. WEISS F, Labrador-Garrido A, Dzamko N, Halliday G, et al
    Immune responses in the Parkinson's disease brain.
    Neurobiol Dis. 2022;168:105700.
    PubMed     Abstract available


  34. HENDERSON MX, Henrich MT, Geibl FF, Oertel WH, et al
    The roles of connectivity and neuronal phenotype in determining the pattern of alpha-synuclein pathology in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 10:105687. doi: 10.1016/j.nbd.2022.105687.
    PubMed     Abstract available


  35. SHEN W, Zhai S, Surmeier DJ
    Striatal synaptic adaptations in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 7:105686. doi: 10.1016/j.nbd.2022.105686.
    PubMed     Abstract available


  36. COUSINEAU J, Plateau V, Baufreton J, Le Bon-Jego M, et al
    Dopaminergic modulation of primary motor cortex: From cellular and synaptic mechanisms underlying motor learning to cognitive symptoms in Parkinson's disease.
    Neurobiol Dis. 2022 Mar 1:105674. doi: 10.1016/j.nbd.2022.105674.
    PubMed     Abstract available


    February 2022
  37. MOLINET-DRONDA F, Blesa J, Del Rey NL, Juri C, et al
    Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism.
    Neurobiol Dis. 2022;167:105669.
    PubMed     Abstract available


  38. BOCCALINI C, Carli G, Pilotto A, Padovani A, et al
    Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes.
    Neurobiol Dis. 2022;167:105668.
    PubMed     Abstract available


  39. GEGG ME, Menozzi E, Schapira AHV
    Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments.
    Neurobiol Dis. 2022;166:105663.
    PubMed     Abstract available


  40. KASEN A, Houck C, Burmeister AR, Sha Q, et al
    Upregulation of alpha-synuclein following immune activation: Possible trigger of Parkinson's disease.
    Neurobiol Dis. 2022 Feb 7:105654. doi: 10.1016/j.nbd.2022.105654.
    PubMed     Abstract available


    January 2022
  41. HORSAGER J, Knudsen K, Sommerauer M
    Clinical and imaging evidence of brain-first and body-first Parkinson's disease.
    Neurobiol Dis. 2022 Jan 11:105626. doi: 10.1016/j.nbd.2022.105626.
    PubMed     Abstract available


  42. WOERMAN AL, Tamguney G
    Body-first Parkinson's disease and variant Creutzfeldt-Jakob disease - similar or different?
    Neurobiol Dis. 2022 Jan 10:105625. doi: 10.1016/j.nbd.2022.105625.
    PubMed     Abstract available


    December 2021
  43. LI J, Chen L, Qin Q, Wang D, et al
    Upregulated hexokinase 2 expression induces the apoptosis of dopaminergic neurons by promoting lactate production in Parkinson's disease.
    Neurobiol Dis. 2021;163:105605.
    PubMed     Abstract available


  44. CHEN H, Wang K, Scheperjans F, Killinger B, et al
    Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.
    Neurobiol Dis. 2021;163:105601.
    PubMed     Abstract available


  45. VAN DEN BERGE N, Ulusoy A
    Animal models of brain-first and body-first Parkinson's disease.
    Neurobiol Dis. 2021;163:105599.
    PubMed     Abstract available


  46. SCHILDER BM, Navarro E, Raj T
    Multi-omic insights into Parkinson's Disease: From genetic associations to functional mechanisms.
    Neurobiol Dis. 2021 Dec 3:105580. doi: 10.1016/j.nbd.2021.105580.
    PubMed     Abstract available


  47. NOVELLO S, Mercatelli D, Albanese F, Domenicale C, et al
    In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.
    Neurobiol Dis. 2021 Dec 3:105579. doi: 10.1016/j.nbd.2021.105579.
    PubMed     Abstract available


  48. BORGHAMMER P, Horsager J, Andersen K, Van Den Berge N, et al
    Neuropathological evidence of body-first vs. brain-first Lewy body disease.
    Neurobiol Dis. 2021;161:105557.
    PubMed     Abstract available


    November 2021
  49. HANG L, Wang Z, Foo ASC, Goh GWY, et al
    Conditional disruption of AMP kinase in dopaminergic neurons promotes Parkinson's disease-associated phenotypes in vivo.
    Neurobiol Dis. 2021;161:105560.
    PubMed     Abstract available


  50. NORDSTROM E, Eriksson F, Sigvardson J, Johannesson M, et al
    ABBV-0805, a novel antibody selective for soluble aggregated alpha-synuclein, prolongs lifespan and prevents buildup of alpha-synuclein pathology in mouse models of Parkinson's disease.
    Neurobiol Dis. 2021 Nov 1:105543. doi: 10.1016/j.nbd.2021.105543.
    PubMed     Abstract available


  51. FERRER-RAVENTOS P, Beyer K
    Alternative platelet activation pathways and their role in neurodegenerative diseases.
    Neurobiol Dis. 2021;159:105512.
    PubMed     Abstract available


  52. JOHNSON ME, Bergkvist L, Stetzik L, Steiner JA, et al
    Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological alpha-synuclein spread in the prodromal preformed fibrils model in young mice.
    Neurobiol Dis. 2021;159:105513.
    PubMed     Abstract available


  53. COSDEN M, Jinn S, Yao L, Gretzula CA, et al
    A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Neurobiol Dis. 2021;159:105507.
    PubMed     Abstract available


  54. BRENDZA R, Lin H, Stark K, Foreman O, et al
    Genetic ablation of Gpnmb does not alter synuclein-related pathology.
    Neurobiol Dis. 2021;159:105494.
    PubMed     Abstract available


  55. ALBANESE F, Mercatelli D, Finetti L, Lamonaca G, et al
    Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Neurobiol Dis. 2021;159:105487.
    PubMed     Abstract available


    October 2021
  56. HU S, Tan J, Qin L, Lv L, et al
    Molecular chaperones and Parkinson's disease.
    Neurobiol Dis. 2021;160:105527.
    PubMed     Abstract available


    August 2021
  57. ALANAZI FI, Al-Ozzi T, Kalia SK, Hodaie M, et al
    Neurophysiological responses of globus pallidus internus during the auditory oddball task in Parkinson's disease.
    Neurobiol Dis. 2021 Aug 27:105490. doi: 10.1016/j.nbd.2021.105490.
    PubMed     Abstract available


  58. TORRES ERS, Stanojlovic M, Zelikowsky M, Bonsberger J, et al
    Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
    Neurobiol Dis. 2021;158:105478.
    PubMed     Abstract available


  59. ARKAN S, Ljungberg M, Kirik D, Hansen C, et al
    DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.
    Neurobiol Dis. 2021 Aug 11:105477. doi: 10.1016/j.nbd.2021.105477.
    PubMed     Abstract available


  60. OLSEN AL, Feany MB
    Parkinson's disease risk genes act in glia to control neuronal alpha-synuclein toxicity.
    Neurobiol Dis. 2021 Aug 11:105482. doi: 10.1016/j.nbd.2021.105482.
    PubMed     Abstract available


  61. RODICHKIN AN, Edler MK, McGlothan JL, Guilarte TR, et al
    Behavioral and neurochemical studies of inherited manganese-induced dystonia-parkinsonism in Slc39a14-knockout mice.
    Neurobiol Dis. 2021 Aug 3:105467. doi: 10.1016/j.nbd.2021.105467.
    PubMed     Abstract available


    July 2021
  62. KAKUSA B, Huang Y, Barbosa DAN, Feng A, et al
    Anticipatory human subthalamic area beta-band power responses to dissociable tastes correlate with weight gain.
    Neurobiol Dis. 2021;154:105348.
    PubMed     Abstract available


    June 2021
  63. ANDREOLI L, Abbaszadeh M, Cao X, Cenci MA, et al
    Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
    Neurobiol Dis. 2021 Jun 18:105429. doi: 10.1016/j.nbd.2021.105429.
    PubMed     Abstract available


    May 2021
  64. FAUSER M, Ricken M, Markert F, Weis N, et al
    Subthalamic nucleus deep brain stimulation induces sustained neurorestoration in the mesolimbic dopaminergic system in a Parkinson's disease model.
    Neurobiol Dis. 2021 May 24:105404. doi: 10.1016/j.nbd.2021.105404.
    PubMed     Abstract available


  65. TOMKINS JE, Manzoni C
    Advances in protein-protein interaction network analysis for Parkinson's disease.
    Neurobiol Dis. 2021;155:105395.
    PubMed     Abstract available


  66. BRAZHNIK E, Novikov N, McCoy AJ, Ilieva NM, et al
    Early decreases in cortical mid-gamma peaks coincide with the onset of motor deficits and precede exaggerated beta build-up in rat models for Parkinson's disease.
    Neurobiol Dis. 2021 May 14:105393. doi: 10.1016/j.nbd.2021.105393.
    PubMed     Abstract available


  67. WESTON LJ, Cook ZT, Stackhouse TL, Sal MK, et al
    In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129.
    Neurobiol Dis. 2021;152:105291.
    PubMed     Abstract available


  68. WIEST C, Tinkhauser G, Pogosyan A, He S, et al
    Subthalamic deep brain stimulation induces finely-tuned gamma oscillations in the absence of levodopa.
    Neurobiol Dis. 2021;152:105287.
    PubMed     Abstract available


    April 2021
  69. YIN Z, Zhu G, Zhao B, Bai Y, et al
    Local field potentials in Parkinson's disease: a frequency-based review.
    Neurobiol Dis. 2021 Apr 28:105372. doi: 10.1016/j.nbd.2021.105372.
    PubMed     Abstract available


  70. PETERS OM, Weiss A, Metterville J, Song L, et al
    Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease.
    Neurobiol Dis. 2021 Apr 20:105368. doi: 10.1016/j.nbd.2021.105368.
    PubMed     Abstract available


    March 2021
  71. BRUMBERG J, Kuzkina A, Lapa C, Mammadova S, et al
    Dermal and cardiac autonomic fiber involvement in Parkinson's disease and multiple system atrophy.
    Neurobiol Dis. 2021 Mar 12:105332. doi: 10.1016/j.nbd.2021.105332.
    PubMed     Abstract available


  72. CHU Y, Kordower JH
    GDNF signaling in subjects with minimal motor deficits and Parkinson's disease.
    Neurobiol Dis. 2021 Mar 5:105298. doi: 10.1016/j.nbd.2021.105298.
    PubMed     Abstract available


  73. ZOU L, Zhang X, Xiong M, Meng L, et al
    Asparagine endopeptidase cleaves synaptojanin 1 and triggers synaptic dysfunction in Parkinson's disease.
    Neurobiol Dis. 2021 Mar 4:105326. doi: 10.1016/j.nbd.2021.105326.
    PubMed     Abstract available


  74. CREED RB, Roberts RC, Farmer CB, McMahon LL, et al
    Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.
    Neurobiol Dis. 2021;150:105246.
    PubMed     Abstract available


    February 2021
  75. JIANG M, Tu HT, Zhang K, Zhang W, et al
    Impaired neurogenesis in the hippocampus of an adult VPS35 mutant mouse model of Parkinson's disease through interaction with APP.
    Neurobiol Dis. 2021 Feb 23:105313. doi: 10.1016/j.nbd.2021.105313.
    PubMed     Abstract available


  76. DE MIRANDA BR, Castro SL, Rocha EM, Bodle CR, et al
    The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    Neurobiol Dis. 2021 Feb 23:105312. doi: 10.1016/j.nbd.2021.105312.
    PubMed     Abstract available


  77. KINNERUP MB, Sommerauer M, Damholdt MF, Schaldemose JL, et al
    Preserved noradrenergic function in Parkinson's disease patients with rest tremor.
    Neurobiol Dis. 2021 Feb 4:105295. doi: 10.1016/j.nbd.2021.105295.
    PubMed     Abstract available


    January 2021
  78. SENCHUK MM, Van Raamsdonk JM, Moore DJ
    Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease.
    Neurobiol Dis. 2021 Jan 12:105267. doi: 10.1016/j.nbd.2021.105267.
    PubMed     Abstract available


  79. BLAUWENDRAAT C, Makarious MB, Leonard HL, Bandres-Ciga S, et al
    A population scale analysis of rare SNCA variation in the UK Biobank.
    Neurobiol Dis. 2021;148:105182.
    PubMed     Abstract available


  80. ANTONAZZO M, Gomez-Urquijo SM, Ugedo L, Morera-Herreras T, et al
    Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor.
    Neurobiol Dis. 2021;148:105214.
    PubMed     Abstract available


    December 2020
  81. YANG J, Luo S, Zhang J, Yu T, et al
    Exosome-mediated delivery of antisense oligonucleotides targeting alpha-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
    Neurobiol Dis. 2020 Dec 6:105218. doi: 10.1016/j.nbd.2020.105218.
    PubMed     Abstract available


    November 2020
  82. ARASARATNAM CJ, Singh-Bains MK, Waldvogel HJ, Faull RLM, et al
    Neuroimaging and neuropathology studies of X-linked dystonia parkinsonism.
    Neurobiol Dis. 2020;148:105186.
    PubMed     Abstract available


  83. AGLIARDI C, Meloni M, Guerini FR, Zanzottera M, et al
    Oligomeric alpha-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease.
    Neurobiol Dis. 2020 Nov 17:105185. doi: 10.1016/j.nbd.2020.105185.
    PubMed     Abstract available


  84. UNDERWOOD CF, Parr-Brownlie LC
    Primary motor cortex in Parkinson's disease: Functional changes and opportunities for neurostimulation.
    Neurobiol Dis. 2020 Nov 2:105159. doi: 10.1016/j.nbd.2020.105159.
    PubMed     Abstract available


    October 2020
  85. WILKINS KB, Parker JE, Bronte-Stewart HM
    Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson's disease.
    Neurobiol Dis. 2020;146:105134.
    PubMed     Abstract available


    September 2020
  86. BAASKE MK, Kormann E, Holt AB, Gulberti A, et al
    Parkinson's disease uncovers an underlying sensitivity of subthalamic nucleus neurons to beta-frequency cortical input in vivo.
    Neurobiol Dis. 2020 Sep 26:105119. doi: 10.1016/j.nbd.2020.105119.
    PubMed     Abstract available


    June 2020
  87. ZHENG C, Xu Y, Chen G, Tan Y, et al
    Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
    Neurobiol Dis. 2020;139:104807.
    PubMed     Abstract available


  88. PELLEGRINI C, Ippolito C, Segnani C, Dolfi A, et al
    Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration.
    Neurobiol Dis. 2020;139:104821.
    PubMed     Abstract available


  89. ANAND N, Holcom A, Broussalian M, Schmidt M, et al
    Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.
    Neurobiol Dis. 2020;139:104786.
    PubMed     Abstract available


    May 2020
  90. FAUSTINI G, Longhena F, Bruno A, Bono F, et al
    Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Neurobiol Dis. 2020;138:104789.
    PubMed     Abstract available


    April 2020
  91. VINUEZA-GAVILANES R, Inigo-Marco I, Larrea L, Lasa M, et al
    N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity.
    Neurobiol Dis. 2020;137:104781.
    PubMed     Abstract available


  92. BAASKE MK, Kramer ER, Meka DP, Engler G, et al
    Parkin deficiency perturbs striatal circuit dynamics.
    Neurobiol Dis. 2020;137:104737.
    PubMed     Abstract available


    February 2020
  93. STOYKA LE, Arrant AE, Thrasher DR, Russell DL, et al
    Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded alpha-synuclein inclusions.
    Neurobiol Dis. 2020;134:104708.
    PubMed     Abstract available


  94. AFGHAH Z, Chen X, Geiger JD
    Role of endolysosomes and inter-organellar signaling in brain disease.
    Neurobiol Dis. 2020;134:104670.
    PubMed     Abstract available


  95. CHEN C, Vincent AE, Blain AP, Smith AL, et al
    Investigation of mitochondrial biogenesis defects in single substantia nigra neurons using post-mortem human tissues.
    Neurobiol Dis. 2020;134:104631.
    PubMed     Abstract available


  96. ALBERQUILLA S, Gonzalez-Granillo A, Martin ED, Moratalla R, et al
    Dopamine regulates spine density in striatal projection neurons in a concentration-dependent manner.
    Neurobiol Dis. 2020;134:104666.
    PubMed     Abstract available


  97. SOLTI K, Kuan WL, Forizs B, Kustos G, et al
    DJ-1 can form beta-sheet structured aggregates that co-localize with pathological amyloid deposits.
    Neurobiol Dis. 2020;134:104629.
    PubMed     Abstract available


  98. YANG SY, Gegg M, Chau D, Schapira A, et al
    Glucocerebrosidase activity, cathepsin D and monomeric alpha-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Neurobiol Dis. 2020;134:104620.
    PubMed     Abstract available


  99. MEZIAS C, Rey N, Brundin P, Raj A, et al
    Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation.
    Neurobiol Dis. 2020;134:104623.
    PubMed     Abstract available


  100. CRESTO N, Gaillard MC, Gardier C, Gubinelli F, et al
    The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Neurobiol Dis. 2020;134:104614.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: